A new report reveals that integrating compliance measures into AI platforms from the outset is crucial for scaling successful initiatives in regulated manufacturing environments, turning potential failures into strategic advantages.
AI initiatives in manufacturing routinely stall not because the technology fails in a lab, but because compliance and governance are treated as afterthoughts. Pilot projects for quality inspection, predictive maintenance and supply-chain optimisation often demonstrate technical promise yet founder when they enter production, delayed by audit, safety and regulatory review that the original architecture cannot satisfy.
A 2025 study by Pertama Partners highlights the scale of the problem: 42% of companies abandoned AI initiatives that year, with the inability to prove business value, data shortcomings and insufficient resources cited as the leading drivers of failure. According to the report, unsuccessful programmes commonly lacked clear objectives, adequate investment in data, realistic resourcing and sustained senior sponsorship , factors that often intersect with governance and compliance gaps. Successful projects, by contrast, tended to align tightly with business outcomes and were prepared to adapt as issues emerged.
For regulated manufacturers, the regulatory bar is explicit and uncompromising. FDA guidance on 21 CFR Part 11 and related predicate rules require electronic records and signatures to be trustworthy, retrievable and maintained in forms equivalent to original paper records. Industry guidance emphasises the need for systems that preserve data integrity, maintain audit trails, and limit unauthorised access. Where AI platforms copy or redistribute operational data without preserving those controls, they create compliance exposure that can force costly redesigns or block deployment entirely.
The architectural choice matters. Platforms that bake governance into the data access layer address several failure modes simultaneously. Key capabilities for regulated operations include deterministic outputs with reproducible data lineage, enforcement of access controls at query time so row-level security and authorisations travel with each request, and comprehensive audit records showing which sources were consulted and by whom. Equally important in many industrial settings is the ability to query data in place so sensitive operational technology (OT) datasets need not be copied into external vector stores or lakes where governance may be harder to guarantee.
Legacy enterprise connectivity and a semantic understanding of manufacturing domain logic can reduce risk in ways generic models struggle to match. Connectivity that leverages mature drivers and integrates with on-premises and hybrid estates allows organisations to host data where policy requires, while a semantic layer that codifies business rules helps ensure that natural-language queries return answers that reflect operational reality rather than probabilistic guesses. That combination also reduces the opportunity for so-called “hallucinations” by constraining responses to governed, context-aware sources.
Practical outcomes are tangible on the factory floor. When engineers can query live sensor streams, maintenance logs and production schedules through a single governed interface, time-to-insight shrinks from days to minutes while compliance teams retain full visibility of access and provenance. Similarly, procurement and production leaders can obtain governed forecasts of inventory risk without exposing downstream teams to data they are not authorised to see, because row-level policies are enforced at query time.
Organisations choosing AI infrastructure for industrial environments should weigh three considerations. First, evaluate how the platform enforces governance during runtime rather than relying on post hoc wrappers. Second, demand deterministic, auditable results that can support regulatory review and incident investigation. Third, prefer connectivity approaches with an enterprise track record in compliance-sensitive environments so IT and audit functions are not forced to learn an entirely new model under operational pressure.
The choice is not merely technical; it is strategic. Industry data and regulatory guidance make clear that many AI ambitions falter where governance is absent or incomplete. Building systems that treat compliance as foundational converts what is often the biggest deployment risk into a competitive advantage: the ability to move from successful pilot to supported production with predictable, auditable outcomes.
According to Pertama Partners, projects that align objectives, invest in data and secure sustained sponsorship are far more likely to persist. Likewise, FDA and industry guidance underline that electronic-records requirements are non-negotiable for manufacturers operating under regulated regimes. Taken together, these realities point to a single lesson for industrial decarbonisation and broader operational-digitalisation programmes: embed governance into architecture from day one so AI becomes a tool for resilient, compliant decarbonisation rather than an orphaned experiment.
- https://insightsoftware.com/blog/how-manufacturing-leaders-deploy-ai-faster-with-governance-first-architecture/ – Please view link – unable to able to access data
- https://www.pertamapartners.com/insights/enterprise-ai-abandonment-2025 – In 2025, 42% of companies abandoned AI initiatives, marking a shift from accepting AI challenges to demanding business results. The primary reasons for abandonment included an inability to demonstrate business value (67%), data issues (58%), and resource constraints (52%). Successful projects were characterised by clear objectives, adequate data investment, realistic resources, sustained sponsorship, and a willingness to pivot. This analysis underscores the importance of aligning AI projects with business goals and ensuring robust data and resource planning to enhance the likelihood of successful AI implementation.
- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application – The FDA’s guidance on 21 CFR Part 11 outlines the scope and application of regulations concerning electronic records and electronic signatures. It specifies that these regulations apply to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under any records requirements set forth in Agency regulations. The guidance also clarifies that while Part 11 remains in effect, the FDA intends to exercise enforcement discretion with respect to certain requirements during its re-examination process.
- https://www.pharmtech.com/view/requirements-electronic-records-contained-21-cfr-211 – This article discusses the regulatory requirements for electronic records as outlined in Title 21 CFR Part 211 and how they intersect with Title 21 CFR Part 11. It highlights that electronic records must be maintained in accordance with the applicable predicate rules, such as 21 CFR 211.68 and 211.180(d), which require records to be retained as original records or true copies. The article emphasises the importance of understanding these requirements to ensure compliance in the pharmaceutical industry.
- https://www.pharmamanufacturing.com/compliance/regulatory-guidance/article/11323001/an-introduction-to-21-cfr-part-11 – An introduction to 21 CFR Part 11, this article explains that the regulation ensures electronic records and signatures are trustworthy, reliable, and equivalent to paper records and handwritten signatures. It defines electronic records as any combination of text, graphics, data, audio, or pictorial information represented in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer. The article provides a high-level overview of the regulation’s scope and applicability in the pharmaceutical industry.
- https://www.pharmaguideline.com/2025/11/21-cfr-part-11-requirements-for-laboratories.html – This article outlines the requirements of 21 CFR Part 11 for laboratories, focusing on ensuring the reliability and integrity of electronic records. It discusses the importance of maintaining electronic records in compliance with FDA regulations, particularly in pharmaceutical laboratories where electronic data systems have replaced paper documentation. The article provides guidance on implementing good documentation practices and system controls to achieve compliance with 21 CFR Part 11.
- https://www.fdaguidelines.com/data-integrity-electronic-records-21-cfr-part-11/ – This guide provides an overview of FDA guidelines on data integrity and electronic records under 21 CFR Part 11. It discusses the importance of ensuring that electronic records and signatures are trustworthy, reliable, and equivalent to paper records. The article highlights the significance of compliance with these regulations to maintain data integrity and meet FDA expectations in the pharmaceutical industry.
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The article was published on April 3, 2026, indicating recent content. However, the study by Pertama Partners referenced within the article is dated February 21, 2026, which raises questions about the freshness of the data presented. Additionally, the article appears to be a republished press release from insightsoftware, which may affect its originality. Further investigation is needed to confirm the originality of the content.
Quotes check
Score:
6
Notes:
The article includes direct quotes attributed to Pertama Partners. However, these quotes cannot be independently verified through available online sources, raising concerns about their authenticity. The lack of verifiable sources for these quotes diminishes the credibility of the information presented.
Source reliability
Score:
5
Notes:
The article originates from insightsoftware, a company that provides solutions for financial reporting and analytics. While insightsoftware is a known entity, its role as the publisher of the article introduces potential bias, as the content may serve promotional purposes. The reliance on a single source for the study’s findings further limits the reliability of the information.
Plausibility check
Score:
7
Notes:
The claims regarding the abandonment of AI initiatives in manufacturing due to governance and compliance issues are plausible and align with industry challenges. However, the lack of independent verification and the potential recycling of content from a press release reduce the overall trustworthiness of these claims.
Overall assessment
Verdict (FAIL, OPEN, PASS): FAIL
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
The article presents information that is potentially outdated and lacks independent verification. The reliance on a single source and the promotional nature of the content further diminish its credibility. Given these concerns, the content does not meet the necessary standards for publication under our editorial guidelines.

